The final, formatted version of the article will be published soon.
SYSTEMATIC REVIEW article
Front. Endocrinol.
Sec. Renal Endocrinology
Volume 16 - 2025 |
doi: 10.3389/fendo.2025.1472531
Peripheral blood copeptin levels in patients with renal dysfunction: A meta-analysis
Provisionally accepted
Wen Yang *
Tiansheng Wang - Binhai Hospital, Peking University, Tianjin, China
Background: Emerging evidence shows the use of copeptin for diagnosis and prognosis of renal disease. Hence, our meta-analysis aimed to evaluate if circulating copeptin level is a biomarker of chronic kidney disease (CKD) severity that could be introduced into clinical practice as a novel biomarker. Methods: The meta-analysis searched for literature published before December 2023 in PubMed and Web of Science. STATA 12.0 software computed the standard mean difference (SMD) and 95% confidence interval (CI). Results: The meta-analysis showed an increased peripheral blood copeptin level in patients with renal dysfunction, compared to healthy controls (HC) (SMD = 0.96, 95% CI = 0.60 to 1.32, p < 0.001). The meta-analysis showed an increased peripheral blood copeptin level in patients with CKD stage 3, compared to patients with CKD stages 1 or 2 (SMD = 0.84, 95% CI = 0.66 to 1.02, p < 0.001). The meta-analysis showed an increased peripheral blood copeptin level in patients with CKD stages 4 or 5, compared to patients with CKD stages 1 or 2 (SMD = 2.19, 95% CI = 1.59 to 2.80, p < 0.001). The meta-analysis showed an increased peripheral blood copeptin level in CKD stages 4 or 5 patients, compared to CKD stage 3 (SMD = 1.10, 95% CI = 0.54 to 1.66, p < 0.001). In addition, the present study reported that peripheral blood copeptin levels presented a moderate negative correlation with the estimated glomerular filtration rate (eGFR). Conclusions: The meta-analysis suggests that copeptin is a prospective blood biomarker that could distinguish between healthy controls and CKD patients and evaluate different CKD stages.
Keywords: Chronic Kidney Disease, Copeptin, Meta-analysis, renal dysfunction, Estimated glomerular filtration rate
Received: 29 Jul 2024; Accepted: 26 Jan 2025.
Copyright: © 2025 Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wen Yang, Binhai Hospital, Peking University, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.